RFC80 polymorphism and plasma levels of methotrexate after HDMTX (nmol/L)
| . | First HDMTX course, 123 patients, GG versus GA/AA, P = .037, n = 123 . | All HDMTX courses, 182 patients, GG versus GA/AA, P = .012, n = 608 . | ||||
|---|---|---|---|---|---|---|
| GG, n = 37 . | GA, n = 58 . | AA, n = 28 . | GG, n = 173 . | GA, n = 307 . | AA, n = 128 . | |
| Low risk | 82 207 | 89 554 | 90 300 | 67 818 | 79 585 | 79 074 |
| High risk | 91 524 | 122 684 | 148 458 | 100 160 | 105 373 | 157 403 |
| . | First HDMTX course, 123 patients, GG versus GA/AA, P = .037, n = 123 . | All HDMTX courses, 182 patients, GG versus GA/AA, P = .012, n = 608 . | ||||
|---|---|---|---|---|---|---|
| GG, n = 37 . | GA, n = 58 . | AA, n = 28 . | GG, n = 173 . | GA, n = 307 . | AA, n = 128 . | |
| Low risk | 82 207 | 89 554 | 90 300 | 67 818 | 79 585 | 79 074 |
| High risk | 91 524 | 122 684 | 148 458 | 100 160 | 105 373 | 157 403 |
ALAT indicates alanine aminotransferase; ALL, acute lymphoblastic leukemia; CI, confidence interval; and HDMTX, high-dose methotrexate.